The NIH-Industry New Therapeutic Uses Pilot Program: Demonstrating the Power of Crowdsourcing

Abstract

Get full access to this article

View all access options for this article.

References

Arcaroli

, Quackenbush

, Dasari

, et al. Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer. Cancer Med., 2012; 1:207–217.

Kendrew

, Odedra

, Logié

, et al. Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies. Cancer Chemother Pharmacol., 2013; 71:1021–1032.

Spijkers-Hagelstein

, Mimoso Pinhanços

, Schneider

, Pieters

, Stam

. Src kinase-induced phosphorylation of annexin A2 mediates glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia. Leukemia., 2013; 27:1063–1071.

Gangadhar

, Clark

, Karrison

, Gajewski

. Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Invest New Drugs., 2013; 31:769–773.